Compare InMode Ltd (INMD) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs UiPath Inc — how do they compare? InMode Ltd trades at $14.07 (market cap $809.93M), while UiPath Inc trades at $13.35 (market cap $6.91B). The key difference: UiPath Inc is far larger — about 8.5× InMode Ltd's market cap, and InMode Ltd is more actively traded (365,490 versus 34,321,250). Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 29 Days and UiPath Inc for 139 Days on average.
| INMD | PATH | |
|---|---|---|
Market Cap | $809.93M | $6.91B |
Volume | 365,490 | 34,321,250 |
Sector | Health | Technology |
52-Week High | $16.62 | $19.29 |
52-Week Low | $12.76 | $9.38 |
Typical Hold Time | 29 Days | 139 Days |
Enterprise Value | $313.27M | $5.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $14.01, up 0.14% on the day, with a bearish technical signal from moving averages and oscillators. The company reported Q2 2026 earnings of $0.35 per share, beating expectations, and maintains a strong gross profit margin of 76.52%. Recent news includes the launch of Morpheus8 Cool and an unsolicited acquisition offer from Steel Partners at $16.75 per share.
The outlook is mixed: valuation metrics like P/E of 11.63 and EV/EBITDA of 4.48 appear attractive, but declining net income and bearish technicals pose risks. Analyst consensus is divided with 45.45% buy ratings, highlighting potential upside from strategic developments against execution challenges.
UiPath (PATH) trades at $13.07, down 0.23% on the day, amid a bearish technical signal and mixed earnings history. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to a projected $1.7B in 2026, while net income is expected to turn positive. Recent news highlights AI partnerships and product innovations, but the stock faces headwinds from cautious analyst sentiment and technical resistance.
The outlook for PATH is cautiously optimistic, with strong revenue growth and a path to profitability offering upside potential, but risks include execution challenges and competitive pressures. The consensus price target of $15.13 suggests moderate upside from current levels, though investor sentiment remains divided.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
